Aware (AWRE) 10-Q 3 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Apr. 19, 2023
Cover [Abstract]
Entity Registrant Name	AWARE, INC.
Entity Central Index Key	0001015739
Trading Symbol	AWRE
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		20,955,339
Document Type	10-Q
Document Period End Date	Mar. 31, 2023
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.01 par value per share
Security Exchange Name	NASDAQ
Entity File Number	000-21129
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2911026
Entity Address, Address Line One	76 Blanchard Road in Burlington
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	781
Local Phone Number	276-4000
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,390	$ 11,749
Marketable securities	18,912	17,229
Accounts receivable, net	2,670	3,317
Unbilled receivables, net	3,483	2,929
Tax receivable	1,362	1,362
Prepaid expenses and other current assets	839	693
Total current assets	35,656	37,279
Property and equipment, net	697	726
Intangible assets, net	2,703	2,806
Goodwill	3,120	3,120
Note receivable	2,632	2,601
Right of use asset	4,470	4,538
Other long-term assets	122	122
Total assets	49,400	51,192
Current liabilities:
Accounts payable	624	639
Accrued expenses	780	1,282
Current portion of operating lease liabilities	623	470
Deferred revenue	3,204	3,411
Current portion of contingent acquisition payment	812
Total current liabilities	6,043	5,802
Long-term deferred revenue	592	322
Long-term operating lease liabilities	3,998	4,047
Long-term portion of contingent acquisition payment		812
Total long-term liabilities	4,590	5,181
Stockholders’ equity:
Preferred stock, $1.00 par value; 1,000,000 shares authorized, none outstanding
Common stock, $.01 par value; 70,000,000 shares authorized; issued and outstanding of 20,955,339 as of March 31, 2023 and 21,093,447 as of December 31, 2022	210	211
Additional paid-in capital	98,286	98,306
Accumulated deficit	(59,766)	(58,198)
Accumulated other comprehensive income (loss)	37	(110)
Total stockholders’ equity	38,767	40,209
Total liabilities and stockholders’ equity	$ 49,400	$ 51,192

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	70,000,000	70,000,000
Common stock, shares issued	20,955,339	21,093,447
Common stock, shares outstanding	20,955,339	21,093,447

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS and COMPREHNSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 4,305	$ 4,692
Costs and expenses:
Cost of services and other revenue	298	314
Research and development	2,381	2,424
Selling and marketing	1,991	1,781
General and administrative	1,504	1,461
Total costs and expenses	6,174	5,980
Operating loss	(1,869)	(1,288)
Interest income	301	9
Net loss	$ (1,568)	$ (1,279)
Net loss per share - basic	$ (0.07)	$ (0.06)
Net loss per share - diluted	$ (0.07)	$ (0.06)
Weighted-average shares – basic	21,033	21,642
Weighted-average shares – diluted	21,033	21,642
Other comprehensive income, net of tax:
Unrealized gain on available-for-sale securities	$ 147
Comprehensive income (loss)	(1,421)	$ (1,279)
Software licenses
Revenue:
Total revenue	2,105	2,628
Software maintenance
Revenue:
Total revenue	1,835	1,661
Services and other
Revenue:
Total revenue	$ 365	$ 403

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (1,568)	$ (1,279)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	149	225
Stock-based compensation	335	430
Interest on note receivable	(31)	(7)
Non-cash lease expense	173
Changes in assets and liabilities:
Accounts receivable	417	(368)
Unbilled receivables	(325)	(88)
Prepaid expenses and other current assets	(181)	(394)
Accounts payable	(15)	190
Accrued expenses	(502)	(650)
Deferred revenue	63	(440)
Net cash used in operating activities	(1,485)	(2,381)
Cash flows from investing activities:
Purchases of property and equipment	(16)
Purchase of marketable securities	(2,752)
Sale of marketable securities	1,250
Investment in note receivable		(2,500)
Net cash used in investing activities	(1,518)	(2,500)
Cash flows from financing activities:
Payments made for taxes of employees who surrendered shares related to unrestricted stock	(15)
Repurchase of common stock	(341)
Net cash used in financing activities	(356)
Decrease in cash and cash equivalents	(3,359)	(4,881)
Cash and cash equivalents, beginning of period	11,749	29,963
Cash and cash equivalents, end of period	$ 8,390	$ 25,082

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2021	$ 41,522	$ 216	$ 97,778	$ (56,472)
Balance (in shares) at Dec. 31, 2021		21,614,000
Issuance of unrestricted stock (in shares)		28,000
Stock-based compensation expense	430		430
Net loss	(1,279)			(1,279)
Balance at Mar. 31, 2022	40,673	$ 216	98,208	(57,751)
Balance (in shares) at Mar. 31, 2022		21,642,000
Balance at Dec. 31, 2022	$ 40,209	$ 211	98,306	(58,198)	$ (110)
Balance (in shares) at Dec. 31, 2022	21,093,447	21,093,000
Issuance of unrestricted stock		$ 1	(1)
Issuance of unrestricted stock (in shares)		62,000
Shares surrendered by employees to pay taxes related to unrestricted stock	$ (15)		(15)
Shares surrendered by employees to pay taxes related to unrestricted stock (in shares)		(9,000)
Repurchase of common stock	(341)	$ (2)	(339)
Repurchase of common stock (in shares)		(191,000)
Stock-based compensation expense	335		335
Other comprehensive income	147				147
Net loss	(1,568)			(1,568)
Balance at Mar. 31, 2023	$ 38,767	$ 210	$ 98,286	$ (59,766)	$ 37
Balance (in shares) at Mar. 31, 2023	20,955,339	20,955,000

Description of the Company and

Description of the Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Company and Basis of Presentation	Note 1 – Description of the Company and Basis of Presentation Description of the Company We are a global leader in biometrics software offerings and solutions. Our portfolio enables government agencies and commercial entities to enroll, identify, authenticate and enable using biometrics, which comprise physiological characteristics, such as fingerprints, faces, irises and voices. • Enroll: Register biometric identities into an organization’s secure database • Identify: Utilize an organization’s secure database to accurately identify individuals using biometric data • Authenticate: Provide frictionless multi-factor, passwordless access to secured accounts and databases with biometric verification • Enable: Manage the lifecycle of secure identities through optimized biometric interchanges We have been engaged in this business since 1993. Our comprehensive portfolio of biometric solutions is based on innovative, robust products designed explicitly for ease of integration, including customer-managed and integration ready biometric frameworks, platforms, software development kits (SDKs) and services. Principal government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Principal commercial applications include mobile enrollment, user authentication, identity proofing, and secure transaction enablement. Our products span multiple biometric modalities including fingerprint, face, iris and voice, and provide interoperable, standards-compliant, field-proven biometric functionality. Our products are used to capture, verify, format, compress and decompress biometric images as well as aggregate, analyze, process, match and transport those images and templates within biometric systems. For large deployments, we may provide project management and software engineering services. We sell our biometrics software products and services globally through a multifaceted distribution strategy using systems integrators, original equipment manufacturers (OEMs), value added resellers (VARs), partners, and directly to end user customers. Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions for Form 10-Q and therefore do not include all information and notes necessary for a complete presentation of our financial position, results of operations and cash flows, in conformity with generally accepted accounting principles. We filed audited financial statements which included all information and notes necessary for such presentation for the two years ended December 31, 2022 in conjunction with our 2022 Annual Report on Form 10-K. This Form 10-Q should be read in conjunction with that Form 10-K. The accompanying unaudited consolidated balance sheets, statements of operations and comprehensive loss, statements of cash flows, and statements of stockholders’ equity reflect all adjustments (consisting only of normal recurring items) which are, in the opinion of management, necessary for a fair presentation of financial position at March 31, 2023, and of operations and cash flows for the interim periods ended March 31, 2023 and 2022. The results of operations for the interim period ended March 31, 2023 are not necessarily indicative of the results to be expected for the year. Principles of Consolidation The consolidated financial statements include the accounts of Aware, Inc. and its subsidiaries, Aware Security Corporation and Fortr3ss, Inc. Intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. The most significant estimates included in the financial statements pertain to revenue recognition, reserves for credit losses, valuation of the contingent acquisition payment, valuation of the investment in the note receivable, goodwill and long-lived asset impairment and valuation allowance for deferred income tax assets. Actual results could differ from those estimates. Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The ASU requires contract assets and contracts liabilities to be accounted for as if they (“the acquirer”) entered into the original contract at the same time and same date as the acquiree. The guidance is effective for reporting periods beginning after December 15, 2022, with early adoption permitted. The adoption of this update did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments , which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This guidance was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates for us, as a smaller reporting company, until fiscal year 2023. The adoption of this update did not have a material impact on our consolidated financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue From Contract With Customer [Abstract]
Revenue Recognition	Note 2 – Revenue Recognition We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, we apply the following five step model: 1. Identify the contract with the customer; 2. Identify the performance obligations in the contract; 3. Determine the transaction price; 4. Allocate the transaction price to the performance obligations in the contract; and 5. Recognize revenue when (or as) each performance obligation is satisfied. We categorize revenue as software licenses, software maintenance, or services and other. Revenue from software licenses is recognized at a point in time upon delivery, provided all other revenue recognition criteria are met. We recognize software maintenance revenue over time on a straight-line basis over the contract period. Services revenue is recognized over time as the services are delivered using an input method (i.e., labor hours incurred as a percentage of total labor hours budgeted), provided all other revenue recognition criteria are met. Other revenue, includes hardware sales that may be included in a software license, is recognized at a point in time upon delivery provided all other revenue recognition criteria are met. In addition to selling software licenses, software maintenance and software services on a standalone basis, a significant portion of our contracts include multiple performance obligations, which require an allocation of the transaction price to each distinct performance obligation based on a relative standalone selling price (“SSP”) basis. The SSP is the price at which we would sell a promised good or service separately to a customer. The best estimate of SSP is the observable price of a good or service when we sell that good or service separately. A contractually stated price or a list price for a good or service may be the SSP of that good or service. We use a range of selling prices to estimate SSP when we sell each of the goods and services separately and need to determine whether there is a discount that needs to be allocated based on the relative SSP of the various goods and services within multiple performance obligation arrangements. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, we typically determine the SSP using an adjusted market assessment approach using information that may include market conditions and other observable inputs. We typically have more than one SSP for individual goods and services due to the stratification of those goods and services by customer. In these instances, we may use information such as the nature of the customer and distribution channel in determining the SSP. When software licenses and significant customization engineering services are sold together, they are accounted for as a combined performance obligation, as the software licenses are generally highly dependent on, and interrelated with, the associated customization services and therefore are not distinct performance obligations. Revenue for the combined performance obligation is recognized over time as the services are delivered using an input method (i.e., labor hours incurred as a percentage of total labor hours budgeted). When subscription-based software is sold, the subscription-based software and software maintenance are generally considered distinct performance obligations. The transaction price is allocated to subscription-based software and the software maintenance based on the relative SSP of each performance obligation. We sell subscription-based software for a fixed fee and/or a usage-based royalty fee, sometimes subject to a minimum guarantee. When the amount is in the form of a fixed fee, including the guaranteed minimum in subscription-based royalties, revenue is allocated to the subscription-based software and recognized at a point in time upon delivery, provided all other revenue recognition criteria are met. Revenue allocated to the software maintenance is recognized over the contract term on a straight-line basis. Any subscription-based software fees earned not subject to the guaranteed minimum or earned in excess of the minimum amount are recognized as revenue when the subsequent usage occurs. Our contracts can include variable fees, such as the option to purchase additional usage of a previously delivered software license. We may also provide pricing concessions to clients, a business practice that also gives rise to variable fees in contracts. We include variable fees in the determination of total transaction price if it is not probable that a future significant reversal of revenue will occur. We use the expected value or most likely value amount, whichever is more appropriate for specific circumstances, to estimate variable consideration, and the estimates are based on the level of historical price concessions offered to clients. The amount of consideration is not adjusted for a significant financing component if the time between payment and the transfer of the related good or service is expected to be one year or less under the practical expedient in the guidance. Our revenue arrangements are typically accounted for under such expedient , as payment is typically due within 30 to 60 days. During the periods ended March 31, 2023 and 2022, none of our contracts contained a significant financing component. Also, to the extent relevant in future periods with our acquisition of FortressID and adaption of our current products to be delivered in a hosted environment with AwareID, we expect to recognize revenue from our SaaS offerings in future periods. SaaS offerings will be recognized ratably over the subscription period. For the three months ended March 31, 2023 and 2022 we did not generate revenue from SaaS contracts. Disaggregation of Revenues We organize ourselves into a single segment that reports to the Chief Executive Officer who is our chief operating decision maker. We conduct our operations in the United States and sell our products and services to domestic and international customers. Revenue generated from the following geographic regions was (in thousands): Three Months Ended 2023 2022 United States $ 2,054 $ 2,036 Rest of World 2,251 2,656 $ 4,305 $ 4,692 Revenue by timing of transfer of goods or services was (in thousands): Three Months Ended 2023 2022 Goods or services transferred at a point in time $ 1,768 $ 2,693 Goods or services transferred over time 2,537 1,999 $ 4,305 $ 4,692 Revenue by product group was (in thousands): Three Months Ended 2023 2022 License and service contracts $ 2,856 $ 3,331 Subscription-based contracts 1,449 1,361 $ 4,305 $ 4,692 Revenue from subscription-based contracts include revenue that may be recognized at a point in time or over time and be part of a fixed fee and or minimum guarantee as well as fees earned and allocated to software maintenance. Contract Balances When the timing of our delivery of goods or services is different from the timing of payments made by customers, we recognize either a contract asset (performance precedes contractual due date) or a contract liability (customer payment precedes performance). Customers that prepay are represented by the deferred revenue below until the performance obligation is satisfied. Our contract assets consist of unbilled receivables. Our contract liabilities consist of deferred (unearned) revenue, which is generally related to software maintenance contracts. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The following tables present changes in our contract assets and liabilities during the three months ended March 31, 2023 and 2022 (in thousands): Balance at Revenue Billings Balance at Three months ended March 31, 2023 Contract assets: Unbilled receivables $ 2,929 $ 2,340 $ ( 1,786 ) $ 3,483 Three months ended March 31, 2022 Contract assets: Unbilled receivables $ 3,087 $ 1,486 $ ( 1,398 ) $ 3,175 Balance at Billings Revenue Balance at Three months ended March 31, 2023 Contract liabilities: Deferred revenue $ 3,733 $ 1,898 $ ( 1,835 ) $ 3,796 Three months ended March 31, 2022 Contract liabilities: Deferred revenue $ 3,740 $ 1,221 $ ( 1,661 ) $ 3,300 Remaining Performance Obligations Remaining performance obligations represent the transaction prices from contracts for which work has not been performed or goods and services have not been delivered. We expect to recognize revenue on approximately 67 % of the remaining deferred revenue over the next 12 months, with the remainder recognized thereafter. As of March 31, 2023, the aggregate amount of the transaction prices allocated to remaining performance obligations for contracts with a duration greater than one year was $ 1.9 million.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 3 – Fair Value Measurements The FASB Codification defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy under the FASB Codification are: Level 1 – valuations that are based on quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date; Level 2 – valuations that are based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly; and Level 3 – valuations that require inputs that are both significant to the fair value measurement and unobservable. Cash and cash equivalents, which primarily include money market mutual funds were $ 8.4 million and $ 11.7 million as of March 31, 2023 and December 31, 2022, respectively. Marketable securities, which primarily include U.S. Treasuries and corporate bonds, were $ 18.9 million and $ 17.2 million as of March 31, 2023 and December 31, 2022, respectively. Our assets and liabilities that are measured at fair value on a recurring basis included the following (in thousands): Fair Value Measurement at March 31, 2023 Using: Quoted Significant Significant Total (Level 1) (Level 2) (Level 3) Assets Money market funds (included in $ 1,463 $ — $ — $ 1,463 Marketable securities 18,912 — — 18,912 Note receivable - — 2,632 2,632 Total assets $ 20,375 $ — $ 2,632 $ 23,007 Liabilities Contingent acquisition payment $ — $ — $ 812 $ 812 Total liabilities $ — $ — $ 812 $ 812 Fair Value Measurement at December 31, Quoted Significant Significant Total (Level 1) (Level 2) (Level 3) Assets Money market funds (included in $ 10,967 $ — $ — $ 10,967 Marketable securities 17,229 — — $ 17,229 Note receivable — — 2,601 2,601 Total assets $ 28,196 $ — $ 2,601 $ 30,797 Liabilities Contingent acquisition payment $ — $ — $ 812 $ 812 Total liabilities $ — $ — $ 812 $ 812 Our investments in marketable securities are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses, net of tax, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity. Marketable securities by security type consisted of the following (in thousands): March 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury notes and bonds $ 13,466 $ 85 $ ( 26 ) $ 13,525 Corporate bonds 5,409 2 ( 24 ) 5,387 $ 18,875 $ 87 $ ( 50 ) $ 18,912 December 31, 2022: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury notes and bonds $ 13,389 $ 24 $ ( 100 ) $ 13,313 Corporate bonds 3,950 — ( 34 ) 3,916 $ 17,339 $ 24 $ ( 134 ) $ 17,229 The investment in the Note Receivable ("Note") with Omlis Limited ("Omlis"), a limited company incorporated and registered in England and Wales and the parent of MIRCAL Technologies Limited ("MIRACL"), was negotiated at an arm’s length basis and the total carrying value of the investment of $ 2.6 million is representative of the fair value of the investment as of March 31, 2023 and December 31, 2022. During the three months ended March 31, 2023 and for the year ended December, 31, 2022, there were no changes in the underlying assumptions of the Note. The change in fair value during the three months ended March 31, 2023 and for the year ended December 31, 2022 was the result of accrued interest. In December 2021, we acquired 100 % of the outstanding shares and acquired all of the assets and liabilities of FortressID for a purchase price of $ 3.4 million, which consisted of $ 2.5 million of cash consideration and contingent acquisition payments which were fair valued at $ 0.9 million at the acquisition date. The maximum contingent acquisition payments at the time of the acquisition was $ 4.0 million and required cash payments of up to $ 2.0 million for set revenue targets in 2022 and another $ 2.0 million for set revenue targets in 2023. No revenue targets were achieved in 2022 and the maximum contingent acquisition payment as of March 31, 2023 is $ 2.0 million. The fair value of our contingent acquisition payment was determined using a Monte Carlo simulation and there was no material change in fair value from December 31, 2022 to March 31, 2023 due to no change in forecasted revenue and a de minimis impact from the present value factor. Changes in Note receivable consisted of the following (in thousands): Three Months Ended March 31, 2023 Amortized Cost Balance as of December 31, 2022 $ 2,601 Accrued interest 31 Balance as of March 31, 2023 $ 2,632

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 4 – Intangible Assets Intangible assets and their estimated useful lives as of March 31, 2023 are as follows (dollars in thousands): Useful Life Gross Accumulated Net Book Customer relationships 8 and 10 years $ 2,680 $ 496 $ 2,184 Developed technology 5 and 7 years 710 210 500 Trade name trademarks 3 and 7 years 30 11 19 $ 3,420 $ 717 $ 2,703 During the three months ended March 31, 2023 and 2022, we recorded $ 0.1 million of intangible assets amortization expense. We expect to record amortization expense for the remainder of 2023 and each subsequent year and thereafter as follows (in thousands): 2023 $ 311 2024 415 2025 407 2026 356 2027 356 Thereafter 858 $ 2,703

Subscription Agreement

Subscription Agreement	3 Months Ended
	Mar. 31, 2023
Capitalization Longterm Debt And Equity [Abstract]
Subscription Agreement	Note 5 – Subscription Agreement On March 11, 2022, concurrently with our entry into a mutual reseller arrangement with MIRACL Technologies Limited (“MIRACL”), we entered into a subscription agreement with Omlis Limited, a limited company incorporated and registered in England and Wales and the parent of MIRACL (“Omlis”). We purchased $ 2.5 million of Omlis’ Note Receivable (“Note”) that accrues interest at 5 % annually with a maturity date of March 11, 2026 . Prior to maturity, we have the right to convert the Note into the securities issued in a future financing at a 20 % discount from the price per share paid by the investors in that financing. If the Note remains outstanding on the maturity date, the Note shall, at the option of the holders of a majority of the outstanding Note, (i) be converted into the most senior shares in Omlis, (ii) be redeemed by payment in cash of the Note and all accrued but unpaid interest or (iii) remain outstanding. In connection with the sale of the Note, Omlis granted us a right of first refusal for 18 months with respect to any proposed sale by Omlis of equity securities constituting 20% or more of the outstanding voting power of Omlis or all or substantially all of the assets of Omlis or any of its material subsidiaries. Also, in connection with the sale of the Note, Omlis issued the Company a warrant that expires on September 11, 2023 , which allows us to purchase up to 8 % of the total equity shares in Omlis at a price per share of $ 33.91 . We recorded the Note and warrants at their fair values in accordance with ASC 825, Financial Instruments, for the Note and ASC 815, Derivatives and Hedging, for the warrants, which were $ 2.6 million and $ 0 , respectively as of March 31, 2023. Interest income of $ 31 thousand and $ 7 thousand was earned during the three month periods ended March 31, 2023 and 2022, respectively. The $ 132 thousand in accrued interest is included in the fair value of the note as of March 31, 2023. We assigned a value of $ 0 to the warrant, since the value was deemed de minimis and was not an integral part of the investment.

Computation of Earnings per Sha

Computation of Earnings per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Computation of Earnings per Share	Note 6 – Computation of Earnings per Share Basic earnings per share is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing net income or loss by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For the purposes of this calculation, stock options are considered common stock equivalents in periods in which they have a dilutive effect. Stock options that are anti-dilutive are excluded from the calculation. Potential common stock equivalents were not included in the per share calculation for diluted earnings per share where we had a net loss and the effect of their inclusion would be anti-dilutive.

Equity and Stock-based Compensa

Equity and Stock-based Compensation	3 Months Ended
	Mar. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity and Stock-based Compensation	Note 7– Equity and Stock-based compensation The following table presents stock-based compensation expenses included in our unaudited consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended 2023 2022 Cost of services and other revenue $ 4 $ 5 Research and development 61 82 Selling and marketing 25 96 General and administrative 245 247 Stock-based compensation expense $ 335 $ 430 Stock Options - We did no t grant stock options in the three months ended March 31, 2023 or 2022. Unrestricted Stock Grants - Our 2001 Nonqualified Stock Plan permits us to grant shares of unrestricted shares of stock to our directors, officers, and employees. Stock-based compensation expense for stock grants is determined based on the fair market value of our stock on the date of grant, provided the number of shares in the grant is fixed on the grant date. We granted 134,211 and issued 61,462 shares of unrestricted stock to directors, officers, and employees during the three months ended March 31, 2023. Of the shares granted in the three months ended March 31, 2023, they are scheduled to be issued in two equal installments shortly after June 30, 2023 and December 31, 2023. We granted 107,921 and issued 28,278 shares of unrestricted stock to directors, officers, and employees during the three months ended March 31, 2022. Of the shares granted in the three months ended March 31, 2022, 61,460 were issued shortly after June 30, 2022 and 46,461 were issued shortly after December 31, 2022. Share Purchases - On March 1, 2022, our Board of Directors authorized a new stock repurchase program pursuant to which we may purchase up to $ 10.0 million of our common stock, of which $ 1.7 million has been repurchased as of March 31, 2023. During the three months ended March 31, 2023 and 2022 we purchased 190,908 and zero shares of our common stock, respectively. The shares may be purchased from time to time in the open market or through privately negotiated transactions at management’s discretion, depending upon market conditions and other factors. The authorization to repurchase shares of our common stock expires on December 31, 2023. Repurchases will be made under the program using our own cash resources and will be in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, and other applicable laws, rules and regulations, which may permit repurchases to occur during periods when we might otherwise be precluded from making purchases under insider trading laws or company policy. The program does not obligate us to acquire any particular amount of common stock and the program may be modified or suspended at any time at our Board of Director’s discretion.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes During the three months ended March 31, 2023 and 2022, we recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated due to the uncertainty of realizing a benefit from those items. We have evaluated the positive and negative evidence bearing upon our ability to realize our deferred tax assets, which primarily consist of net operating loss carryforwards and research and development tax credits. We considered the history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and we have concluded that it is more likely than not that we will not realize the benefits of our deferred tax assets. As a result, as of March 31, 2023 and December 31, 2022, we recorded a full valuation allowance against our net deferred tax assts. The carryback of the estimated loss would result in a refundable federal tax credit of approximately $ 1.4 million and an increase in research credit carryforwards previously utilized. The federal tax credit can be refunded in the future, as we decided to carry back the loss reported on the filed 2020 tax return. Upon filing our 2020 tax return and the related carry back claim that is on file with the IRS as of March 31, 2022, we classified the federal tax credit as a current receivable which has yet to be received as of March 31, 2023. Due to the recent loss history, continued investments in the Company, and our future projections of income, we will benefit from the 2020 loss to the extent of the available tax refund and will maintain a full valuation allowance on all other deferred tax assets, including any increase in research credit carryforward resulting from a potential carryback.

Description of the Company an_2

Description of the Company and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions for Form 10-Q and therefore do not include all information and notes necessary for a complete presentation of our financial position, results of operations and cash flows, in conformity with generally accepted accounting principles. We filed audited financial statements which included all information and notes necessary for such presentation for the two years ended December 31, 2022 in conjunction with our 2022 Annual Report on Form 10-K. This Form 10-Q should be read in conjunction with that Form 10-K. The accompanying unaudited consolidated balance sheets, statements of operations and comprehensive loss, statements of cash flows, and statements of stockholders’ equity reflect all adjustments (consisting only of normal recurring items) which are, in the opinion of management, necessary for a fair presentation of financial position at March 31, 2023, and of operations and cash flows for the interim periods ended March 31, 2023 and 2022. The results of operations for the interim period ended March 31, 2023 are not necessarily indicative of the results to be expected for the year.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Aware, Inc. and its subsidiaries, Aware Security Corporation and Fortr3ss, Inc. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. The most significant estimates included in the financial statements pertain to revenue recognition, reserves for credit losses, valuation of the contingent acquisition payment, valuation of the investment in the note receivable, goodwill and long-lived asset impairment and valuation allowance for deferred income tax assets. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The ASU requires contract assets and contracts liabilities to be accounted for as if they (“the acquirer”) entered into the original contract at the same time and same date as the acquiree. The guidance is effective for reporting periods beginning after December 15, 2022, with early adoption permitted. The adoption of this update did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments , which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This guidance was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates for us, as a smaller reporting company, until fiscal year 2023. The adoption of this update did not have a material impact on our consolidated financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue From Contract With Customer [Abstract]
Schedule of Revenue Generated from Geographic Regions	Revenue generated from the following geographic regions was (in thousands): Three Months Ended 2023 2022 United States $ 2,054 $ 2,036 Rest of World 2,251 2,656 $ 4,305 $ 4,692
Schedule of Revenue by Timing of Transfer of Goods or Services	Revenue by timing of transfer of goods or services was (in thousands): Three Months Ended 2023 2022 Goods or services transferred at a point in time $ 1,768 $ 2,693 Goods or services transferred over time 2,537 1,999 $ 4,305 $ 4,692
Schedule of Revenue by Contract Type	Revenue by product group was (in thousands): Three Months Ended 2023 2022 License and service contracts $ 2,856 $ 3,331 Subscription-based contracts 1,449 1,361 $ 4,305 $ 4,692
Schedule of Changes in Contract Assets and Liabilities	The following tables present changes in our contract assets and liabilities during the three months ended March 31, 2023 and 2022 (in thousands): Balance at Revenue Billings Balance at Three months ended March 31, 2023 Contract assets: Unbilled receivables $ 2,929 $ 2,340 $ ( 1,786 ) $ 3,483 Three months ended March 31, 2022 Contract assets: Unbilled receivables $ 3,087 $ 1,486 $ ( 1,398 ) $ 3,175 Balance at Billings Revenue Balance at Three months ended March 31, 2023 Contract liabilities: Deferred revenue $ 3,733 $ 1,898 $ ( 1,835 ) $ 3,796 Three months ended March 31, 2022 Contract liabilities: Deferred revenue $ 3,740 $ 1,221 $ ( 1,661 ) $ 3,300

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Our assets and liabilities that are measured at fair value on a recurring basis included the following (in thousands): Fair Value Measurement at March 31, 2023 Using: Quoted Significant Significant Total (Level 1) (Level 2) (Level 3) Assets Money market funds (included in $ 1,463 $ — $ — $ 1,463 Marketable securities 18,912 — — 18,912 Note receivable - — 2,632 2,632 Total assets $ 20,375 $ — $ 2,632 $ 23,007 Liabilities Contingent acquisition payment $ — $ — $ 812 $ 812 Total liabilities $ — $ — $ 812 $ 812 Fair Value Measurement at December 31, Quoted Significant Significant Total (Level 1) (Level 2) (Level 3) Assets Money market funds (included in $ 10,967 $ — $ — $ 10,967 Marketable securities 17,229 — — $ 17,229 Note receivable — — 2,601 2,601 Total assets $ 28,196 $ — $ 2,601 $ 30,797 Liabilities Contingent acquisition payment $ — $ — $ 812 $ 812 Total liabilities $ — $ — $ 812 $ 812
Summary of Marketable Securities by Security Type	Marketable securities by security type consisted of the following (in thousands): March 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury notes and bonds $ 13,466 $ 85 $ ( 26 ) $ 13,525 Corporate bonds 5,409 2 ( 24 ) 5,387 $ 18,875 $ 87 $ ( 50 ) $ 18,912 December 31, 2022: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Treasury notes and bonds $ 13,389 $ 24 $ ( 100 ) $ 13,313 Corporate bonds 3,950 — ( 34 ) 3,916 $ 17,339 $ 24 $ ( 134 ) $ 17,229
Summary of Changes in Note Receivable	Changes in Note receivable consisted of the following (in thousands): Three Months Ended March 31, 2023 Amortized Cost Balance as of December 31, 2022 $ 2,601 Accrued interest 31 Balance as of March 31, 2023 $ 2,632

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets and Estimated Useful Lives	Intangible assets and their estimated useful lives as of March 31, 2023 are as follows (dollars in thousands): Useful Life Gross Accumulated Net Book Customer relationships 8 and 10 years $ 2,680 $ 496 $ 2,184 Developed technology 5 and 7 years 710 210 500 Trade name trademarks 3 and 7 years 30 11 19 $ 3,420 $ 717 $ 2,703
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	We expect to record amortization expense for the remainder of 2023 and each subsequent year and thereafter as follows (in thousands): 2023 $ 311 2024 415 2025 407 2026 356 2027 356 Thereafter 858 $ 2,703

Equity and Stock-based Compen_2

Equity and Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock-based Compensation Expenses Included in Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)	The following table presents stock-based compensation expenses included in our unaudited consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended 2023 2022 Cost of services and other revenue $ 4 $ 5 Research and development 61 82 Selling and marketing 25 96 General and administrative 245 247 Stock-based compensation expense $ 335 $ 430

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Revenue From Contract With Customer [Abstract]
Practical expedient for financing components	true
Minimum period of payment of transaction price in contract with customer	30 days
Maximum period of payment of transaction price in contract with customer	60 days
Percentage of remaining performance obligations expected to be recognized as revenue	67%
remaining deferred revenue	12 months
Revenue recognition performance obligation transaction prices	$ 1.9
Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]	true

Revenue Recognition - Revenue G

Revenue Recognition - Revenue Generated Following Geographic Regions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,305	$ 4,692
Operating Segments
Disaggregation of Revenue [Line Items]
Total revenue	4,305	4,692
Operating Segments | United States
Disaggregation of Revenue [Line Items]
Total revenue	2,054	2,036
Operating Segments | Rest of World
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,251	$ 2,656

Revenue Recognition - Revenue b

Revenue Recognition - Revenue by Timing of Transfer of Goods or Services (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,305	$ 4,692
Goods or services transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	1,768	2,693
Goods or services transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,537	$ 1,999

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenue by Contract Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,305	$ 4,692
License and Service Contracts
Disaggregation of Revenue [Line Items]
Total revenue	2,105	2,628
Operating Segments
Disaggregation of Revenue [Line Items]
Total revenue	4,305	4,692
Operating Segments | License and Service Contracts
Disaggregation of Revenue [Line Items]
Total revenue	2,856	3,331
Operating Segments | Subscription-based Contracts
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,449	$ 1,361

Revenue Recognition - Changes i

Revenue Recognition - Changes in Contract Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Unbilled receivables, Balance at Beginning of Period	$ 2,929	$ 3,087
Unbilled receivables, Revenue Recognized In Advance of Billings	2,340	1,486
Unbilled receivables, Billings	(1,786)	(1,398)
Unbilled receivables, Balance at End of Period	$ 3,483	$ 3,175

Revenue Recognition - Changes_2

Revenue Recognition - Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Deferred revenue, Balance at Beginning of Period	$ 3,733	$ 3,740
Deferred revenue, Billings	1,898	1,221
Deferred revenue, Revenue Recognized	(1,835)	(1,661)
Deferred revenue, Balance at End of Period	$ 3,796	$ 3,300

Fair Value Measurements - Addit

Fair Value Measurements - Additional information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Available-for-sale Securities
Cash and cash equivalents		$ 8,390		$ 11,749
Marketable securities		18,912		17,229
Maximum
Schedule of Available-for-sale Securities
Contingent consideration earn out payable	$ 4,000
Earn out cash payments				2,000
Maximum | Scenario Forecast
Schedule of Available-for-sale Securities
Earn out cash payments			$ 2,000
Fortress ID
Schedule of Available-for-sale Securities
Percentage of ownership control	100%
Business acquisition, purchase price	$ 3,400
Business acquisition, earnout with fair value	$ 900
Fortress ID | Maximum
Schedule of Available-for-sale Securities
Contingent consideration earn out payable		2,000
U.S. Treasuries and Corporate Bonds [Member]
Schedule of Available-for-sale Securities
Marketable securities		18,900		17,200
Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities
Total fair value of the instrument		2,632		2,601
Fair Value, Measurements, Recurring [Member] | Note Receivable | Omlis Limited
Schedule of Available-for-sale Securities
Total fair value of the instrument		$ 2,600		$ 2,600

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Available-for-sale Securities
Marketable securities	$ 18,912	$ 17,229
Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities
Note receivable	2,632	2,601
Total assets	23,007	30,797
Contingent acquisition payment	812	812
Total liabilities	812	812
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of Available-for-sale Securities
Note receivable	0	0
Total assets	20,375	28,196
Contingent acquisition payment	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2)
Schedule of Available-for-sale Securities
Note receivable	0	0
Total assets	0	0
Contingent acquisition payment	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3)
Schedule of Available-for-sale Securities
Note receivable	2,632	2,601
Total assets	2,632	2,601
Contingent acquisition payment	812	812
Total liabilities	812	812
Fair Value, Measurements, Recurring [Member] | Money market funds (included in cash and cash equivalents)
Schedule of Available-for-sale Securities
Money market funds (included in cash and cash equivalents)	1,463	10,967
Fair Value, Measurements, Recurring [Member] | Money market funds (included in cash and cash equivalents) | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of Available-for-sale Securities
Money market funds (included in cash and cash equivalents)	1,463	10,967
Fair Value, Measurements, Recurring [Member] | Money market funds (included in cash and cash equivalents) | Significant Other Observable Inputs (Level 2)
Schedule of Available-for-sale Securities
Money market funds (included in cash and cash equivalents)	0	0
Fair Value, Measurements, Recurring [Member] | Money market funds (included in cash and cash equivalents) | Significant Unobservable Inputs (Level 3)
Schedule of Available-for-sale Securities
Money market funds (included in cash and cash equivalents)	0	0
Fair Value, Measurements, Recurring [Member] | Marketable securities
Schedule of Available-for-sale Securities
Marketable securities	18,912	17,229
Fair Value, Measurements, Recurring [Member] | Marketable securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of Available-for-sale Securities
Marketable securities	18,912	17,229
Fair Value, Measurements, Recurring [Member] | Marketable securities | Significant Other Observable Inputs (Level 2)
Schedule of Available-for-sale Securities
Marketable securities	0	0
Fair Value, Measurements, Recurring [Member] | Marketable securities | Significant Unobservable Inputs (Level 3)
Schedule of Available-for-sale Securities
Marketable securities	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Marketable Securities by Security Type (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 18,875	$ 17,339
Gross Unrealized Gains	87	24
Gross Unrealized Losses	(50)	(134)
Fair Value	18,912	17,229
U.S. Treasury Notes and Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	13,466	13,389
Gross Unrealized Gains	85	24
Gross Unrealized Losses	(26)	(100)
Fair Value	13,525	13,313
Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,409	3,950
Gross Unrealized Gains	2	0
Gross Unrealized Losses	(24)	(34)
Fair Value	$ 5,387	$ 3,916

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Note Receivable (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Beginning Balance	$ 2,601
Note Receivable
Schedule Of Available For Sale Securities [Line Items]
Accrued Interest	31
Ending Balance	$ 2,632

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 3,120		$ 3,120
Maximum
Business Acquisition [Line Items]
Contingent consideration earn out payable	$ 4,000
Earn out cash payments				$ 2,000
Maximum | Scenario Forecast
Business Acquisition [Line Items]
Earn out cash payments			$ 2,000
Fortress ID
Business Acquisition [Line Items]
Percentage of ownership control	100%
Business acquisition, purchase price	$ 3,400
Business acquisition, cash consideration	2,500
Business acquisition, earnout with fair value	$ 900
Fortress ID | Maximum
Business Acquisition [Line Items]
Contingent consideration earn out payable		$ 2,000

Acquisition - Summary of Fair V

Acquisition - Summary of Fair Value of Assets Acquired and Liabilities Assumed At Date of Acquisition (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 3,120	$ 3,120

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets and Estimated Useful Lives (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 3,420
Accumulated Amortization	717
Net Book Value	2,703
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross Amount	2,680
Accumulated Amortization	496
Net Book Value	$ 2,184
Customer Relationships | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Life	8 years
Customer Relationships | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Life	10 years
Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 710
Accumulated Amortization	210
Net Book Value	$ 500
Developed Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Life	5 years
Developed Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Life	7 years
Trade Name Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 30
Accumulated Amortization	11
Net Book Value	$ 19
Trade Name Trademarks | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Life	3 years
Trade Name Trademarks | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Life	7 years

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 0.1	$ 0.1

Intangible Assets - Schedule of

Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Finite Lived Intangible Assets Net Amortization Expense Rolling Maturity [Abstract]
2023	$ 311
2024	415
2025	407
2026	356
2027	356
Thereafter	858
Net Book Value	$ 2,703

Subscription Agreement - Additi

Subscription Agreement - Additional Information (Details) - USD ($)		3 Months Ended
	Mar. 11, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Schedule Of Capitalization Longterm Debt [Line Items]
Note receivable		$ 2,632,000		$ 2,601,000
Interest income		301,000	$ 9,000
Omlis Limited | Warrant
Schedule Of Capitalization Longterm Debt [Line Items]
Warrants expire date	Sep. 11, 2023
Equity shares purchase price per shares	$ 33.91
Investment in warrant equity security		$ 0
Omlis Limited | Maximum | Warrant
Schedule Of Capitalization Longterm Debt [Line Items]
Issuance of warrants purchase percentage	8%
Note Receivable | Omlis Limited
Schedule Of Capitalization Longterm Debt [Line Items]
Convertible Note amount	$ 2,500,000
Interest rate percentage	5%
Maturity date	Mar. 11, 2026
Discount from effective price per share paid by investors, percentage	20%
Sale of note, description		Omlis granted us a right of first refusal for 18 months with respect to any proposed sale by Omlis of equity securities constituting 20% or more of the outstanding voting power of Omlis or all or substantially all of the assets of Omlis or any of its material subsidiaries.
Note receivable		$ 2,600,000
Interest income		31,000	$ 7,000
Accrued interest included in fair value of note		$ 132,000

Computation of Earnings per S_2

Computation of Earnings per Share - Schedule of Net loss per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss	$ (1,568)	$ (1,279)
Shares outstanding:
Weighted-average common shares outstanding (in shares)	21,033	21,642
Diluted shares outstanding (in shares)	21,033	21,642
Net income (loss) per share - basic	$ (0.07)	$ (0.06)
Net income (loss) per share - diluted	$ (0.07)	$ (0.06)

Equity and Stock-based Compen_3

Equity and Stock-based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 335	$ 430
Cost of services and other revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	4	5
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	61	82
Selling and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	25	96
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 245	$ 247

Equity and Stock-based Compen_4

Equity and Stock-based Compensation - Stock Option Grants and Unrestricted Stock Grants (Details)	1 Months Ended	3 Months Ended		12 Months Ended
	Jul. 31, 2022 shares	Mar. 31, 2023 Installment shares	Mar. 31, 2022 shares	Dec. 31, 2022 shares
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options granted		0	0
Unrestricted Stock | Stock Option Plan2001 [Member] | 2022 Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of unrestricted stock granted		134,211	107,921
Number of shares issued	61,460	61,462	28,278	46,461
Unrestricted Stock | Stock Option Plan2001 [Member] | 2022 Grant | Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of installment | Installment		2

Equity and Stock-based Compen_5

Equity and Stock-based Compensation - Share Purchases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 01, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Repurchase of common stock	$ 341
Share Purchases
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock authorized for repurchase			$ 10,000
Repurchase of common stock	$ 1,700
Number of stock repurchased	190,908	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax benefits for net operating losses	$ 0	$ 0
Estimated benefit of federal tax refund	$ 1,400,000